Physicochemical Characterization and Dissolution Properties of Meloxicam-Gelucire 50/13 Binary Systems by El-Badry, Mahmoud
Sci  Pharm   www.scipharm.at 
Research article  Open Access 
Physicochemical Characterization  
and Dissolution Properties of  
Meloxicam-Gelucire 50/13 Binary Systems 
Mahmoud EL-BADRY 
1,2 
1 Department of Pharmaceutics, College of Pharmacy, King Saud University, P.O. BOX 2457, Riyadh 11451, 
Saudi Arabia. 
2 Department of Pharmaceutics, Faculty of Pharmacy, Assiut University 71526, Assiut, Egypt. 
E-mail: melbadry14@yahoo.com 
Sci Pharm. 2011; 79: 375–386        doi:10.3797/scipharm.1101-22 
Published:   April 10
th  2011     Received:    January  29
th 2011 
Accepted:   April   6
th 2011 
This article is available from: http://dx.doi.org/10.3797/scipharm.1101-22 
© El-Badry; licensee Österreichische Apotheker-Verlagsgesellschaft m. b. H., Vienna, Austria. 
This is an Open Access article distributed under the terms of the Creative Commons Attribution License 
(http://creativecommons.org/licenses/by/3.0/), which permits unrestricted use, distribution, and reproduction 
in any medium, provided the original work is properly cited. 
Abstract 
A solid dispersion of Meloxicam (MX), a poorly soluble, non steroidal anti-
inflammatory drug, and Gelucire 50/13 was prepared by spray drying. Spherical 
microparticles were yielded with smooth surfaces as observed by scanning 
electron microscopy. According to differential scanning calorimetry and powder 
X-ray diffractometry analysis, MX was transformed from the crystalline state to 
the amorphous state as confirmed by the disappearance of its melting peak and 
the crystalline peaks. The dissolution tests at pH 7.4 revealed that the 
dissolution rate of encapsulated MX was 2.5-fold higher than that of the 
corresponding physical mixture and fourfold higher than the drug alone, 
respectively. The microparticles prepared at a ratio of 1:4 (drug/Gelucire) 
exhibited a 4-fold higher anti-inflammatory activity on the paw edema of rats in 
comparison to the drug alone. All in all, this work reveals that spray drying is a 
suitable technique for preparation of solid dispersions with improved 
biopharmaceutical and pharmacological characteristics of MX. 
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Introduction 
Meloxicam (MX), 4-hydroxy-2-methyl-N-(5-methyl-1,3-thiazol-2-yl)-2H-1,2-benzothiazine-
3-carboxamide 1,1-dioxide, is a non-steroidal anti-inflammatory drug (NSAID). MX is a 
potent inhibitor of cyclogenase (COX), and in several models exhibits selectivity for the 
inducible isoenzyme COX2. It is used to treat rheumatoid arthritis, osteoarthritis and 
ankylosing spondylitis. [1–4]. Similar to many other NSAIDs, MX is practically insoluble in 
water and can be graded in class II, of the Biopharmaceutical Classification System, which 
means low aqueous solubility and rapid absorption (high permeability) through 
gastrointestinal tract [5]. Gelucire 50/13 is an excipient composed of fatty acid (C16 and 
C18) esters of glycerol, PEG esters and free PEG. It melts at approximately 50°C and has 
hydrophilic-lipophilic balance (HLB) value of 13 [6, 7]. Gelucires found broad application in 
pharmaceutical formulations e.g. the preparation of fast release and sustained release 
formulations [6]. Gelucires are among the several carriers having been employed in 
preparing solid dispersions [8–10]. 
The spray-drying technique is extensively used in the pharmaceutical industry to produce 
raw drug, excipients or microparticles, as an alternative to emulsification methods. This 
technique transforms the liquid feed into a dry powder in one step and is feasible for the 
scaling-up of the microencapsulation, continuous particle processing operations and can 
be applied to a wide variety of materials. Spray drying can be also used to enhance the 
solubility and improve particulate design [11–14]. 
The purpose of the current study is to characterize the solid-state properties of the solid 
dispersion system of Meloxicam in Gelucire 50/13 prepared at different ratios using the 
spray drying technique. The methods for characterization were scanning electron 
microscopy (SEM), differential scanning calorimetry (DSC), and powder X-ray diffraction 
(XRD). Moreover, solubility and dissolution studies were performed to compare the 
characteristics of the solid dispersion with the pure drug or physical mixture (PM). Also, the 
anti-inflammatory activity of the microparticles on the hind paw edema of rats was studied.  
Results and discussion 
Spray drying is a rapid and simple process to prepare microparticles. The setting of 
different parameters, however, can affect the quality of final product. In addition, the rapid 
evaporation of the solvent from the droplets will influence the crystalline structures of spray 
dried glycerides [15]. To overcome the melting of the produced microparticles on the 
surface of the collector vessel of the spray drying apparatus during the process was 
attempted to be overcome by addition of Aerosil 200. Different drug/carrier ratios were 
used in this study. Spray drying at the parameters set yielded microparticulate solid 
dispersions (SD) with 70–75 % yield and the entrapment efficiency of the drug amounted 
to 90 -95 %. Therefore, the spray drying method is applicable for the preparation of SD.  
Scanning electron microscopy (SEM) 
SEM of the raw materials revealed that MX was characterized by irregular shaped crystals 
whereas Gelucire 50/13 formed big polygonal particles (Fig. 1A, B). The physical mixture 
at a ratio of 1:4 (MX: Gelucire, w/w; PM) contains the characteristic MX crystals with 
adhering and free Gelucire 50/13 particles (Fig. 1C). In contrast, the spray dried 
microparticles prepared from a 1:1 mixture of MX and Gelucire 50/13 represented small   Physicochemical Characterization and Dissolution Properties of Meloxicam-Gelucire 50/13 Binary… 377 
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homogenous and amorphous aggregates of spherical particles with smooth surfaces 
(Fig. 1D), while spray dried microparticles prepared from a 1:4 (w/w) mixture of MX and 
Gelucire were larger spherical particles with rough surfaces (Fig. 1E). Based on the scale, 
SD particles are smaller than 10 µm. 
Differential scanning calorimetry (DSC) 
Differential scanning calorimetry (DSC) offers information about melting, crystallization, 
decomposition or a change in heat capacity and is useful to assess the physicochemical 
status of the entrapped drug as well as the interaction among different compounds. 
Meloxicam (MX) showed an endothermic peak at 262 °C corresponding to its melting point 
[16], whereas Gelucire 50/13 showed a broad melting endotherme at 48.5 °C (Fig. 2) [17]. 
The physical mixture (PM) 1:4 exhibited a weak broad peak at 48.5 °C corresponding to 
Gelucire 50/13 while the peak corresponding to the drug was shifted to 258 °C and 
became broad and very weak due to dilution of the drug. In contrast, the characteristic 
peak of the drug disappeared in all thermograms of spray dried particles. Thus, the 
crystalline drug was dissolved in the melted carrier and its physical status changed to the 
amorphous one. This finding is in agreement with Agnivesh et al. 2009 [18], who reported 
that disappearance of the characteristic peaks of the valsartan dispersed in Gelucire 50/13 
is due to melting of the drug in the matrix.  
 
Fig. 1.   SEM images of meloxicam (A), Gelucire 50/13 (B), physical mixture 
Gelucire/meloxicam 1:4 (C), solid dispersion Gelucire/meloxicam 1:1 (D) and 
solid dispersion Gelucire/meloxicam 1:4 (E).  378 M.  El-Badry:   
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Fig. 2.   Differential scanning calorimetry of MX (drug), Gelucire (gelu) its physical 
mixture (PM) and spray dried microparticles (SD) at different ratios of MX/ 
Gelucire (w/w). 
 
Fig. 3.   X-ray diffraction of MX (drug), Gelucire (gelu), its physical mixture (PM) and 
spray dried microparticles (SD) at different ratios of MX/ Gelucire (w/w). 
X-ray diffraction (XRD) 
As MX is highly crystalline characteristic sharp peaks appeared in XRD at diffraction 
angles of 2θ at 15.65, 19.31, 19.98, 26.58 and 27.08 (Fig. 3). Gelucire 50/13 also exhibited   Physicochemical Characterization and Dissolution Properties of Meloxicam-Gelucire 50/13 Binary… 379 
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some crystallinity as indicated by the two characteristic peaks of high intensity at 19.26 
and 23.5 at 2θ. All the features already observed for the single compounds were present in 
their PMs with lower intensity, but no interaction could be detected. The decrease in the 
intensity of MX-peaks in the diffractograms of the SD-microparticles became apparent at 
the1:1 ratio and further decreased with decreasing MX-content until complete 
disappearance at the 1:4 ratio. Thus, the spray drying process decreased the crystallinity 
or the disordered molecular dispersion of the crystalline drug in the Gelucire matrix during 
rapid drying of the sprayed droplet. No new peaks could be observed suggesting the 
absence of any chemical interaction between MX and the matrix [19]. 
Solubility study 
The solubility of MX was determined in 0.2 M phosphate buffer pH 7.4 at 37 °C (table 1). In 
general, the presence of Gelucire 50/13 increased the solubility of MX. In case of a PM at 
the ratio 1:4 (MX:Gelucire, w/w) the solubility of MX was enhanced about 1.64 fold. In 
contrast, a SD prepared at the same ratio increased the solubility of the drug additionally 
3.85 fold. In case of SDs, the increasing solubility of MX with increasing Gelucire-content 
is higher than that of the PM and might be attributed to the decreasing crystallinity of the 
drug as confirmed by DSC and XRD.  
Tab. 1.  Solubility and R.D.R. of MX, PM and SD microparticles in 0.2 M phosphate 
buffer pH 7.4. 
System Ratio 
MX:Gelucire 
(w/w) 
Solubility 
(Mx10
-3) 
5 min  R.D.R. 
10 min 
15 min 
MX 
PM 
SD 
– 
1:4 
1:1 
1:2 
1:4 
1.736 
2.852 
3.752 
4.850 
6.685 
– 
1.80 
2.50 
3.50 
7.00 
– 
1.78 
2.14 
3.21 
5.93 
– 
1.72 
2.22 
3.05 
5.00 
R.D.R. represents the ratio between the amounts of drug dissolved from 
formulation and that from drug alone.  
 
Dissolution study 
The dissolution rate of MX was extremely low, with only about 10 % and 28 % of drug 
dissolved after 120 min in 0.1 N HCl and phosphate buffer pH 7.4, respectively (Fig. 4, 5). 
This might be attributed to poor wettability and particle agglomeration as indicated by 
floating of the powdered drug on the surface of the media [16]. Similar to that already 
observed during dissolution studies, the dissolution rate of MX was considerably higher in 
presence of Gelucire. In artificial gastric juice, the increase in MX-dissolution was about 
1.5 fold in case of PM 1:4, while it was about 3.5 fold for SD after 2h. In artificial intestinal 
juice (Fig. 5) the increase in dissolution of MX was more pronounced. In case of PM the 
amount of MX dissolved after 2h exceeded that of MX alone 1.5-fold, in case of SD 1:1 
2-fold and finally in case of SD 1:4 3.4-fold. This might be due to increased wettability of 
the drug and decreased surface tension of the medium due to presence of Gelucire 
[20, 21]. Agnivesh et al. [18] reported that enhancement of dissolution of valsartan from its 
solid dispersion was due to lack of crystallinity, increased wettability and reduced particle  
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Fig. 4.   Dissolution profile of MX in 0.1 N HCL from its powder, PM and SDs of MX and 
Gelucire 50/13. 
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Fig. 5.   Dissolution profile of MX in 0.2 M phosphate buffer pH 7.4 from its powder, PM 
and SDs of MX and Gelucire 50/13.   Physicochemical Characterization and Dissolution Properties of Meloxicam-Gelucire 50/13 Binary… 381 
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size of the drug. For a more detailed view, the relative dissolution rate (R.D.R.) values 
were calculated which represent the ratio between the amount of drug dissolved from the 
formulation (PM or SD) and that of the pure drug (Table1). Accordingly, the dissolution rate 
increased following the order SD 1:4 > SD 1:2 > SD 1:1 > PM 1:4. Similar observations 
have been reported for nifedipine/Pluronic F68 and nifedipine/Gelucire 50/13 solid 
dispersions where the solubility of poorly water-soluble nifedipine was improved by PM or 
SDs [17]. Also in case of glibenclamide a similar strategy led to accelerated and improved 
in-vitro dissolution that enhanced the hypoglycemic effect [22].  
Anti-inflammatory activity  
The anti-inflammatory activity of the formulations was assessed by the carrageenan 
induced paw edema method scoring the swelling of edema due to presence of the 
formulations, as compared to the control. Table 2 illustrates the anti-inflammatory activity 
of different prepared microparticles, PM and drug alone on the hind paw of the rats. All the 
prepared microparticles exerted significant effects (p < 0.05) as anti-inflammatory vehicles, 
but at extent (Figure 6). The rank order of edema inhibition applying this method followed 
the order SD 1:4 > SD 1:1 > PM 1:4 > MX > control. 
 
0
20
40
60
80
100
120
01234567
time (hr.)
%
 
S
w
e
l
l
i
n
g
 
o
f
 
i
n
d
u
c
e
d
 
e
d
e
m
a
Control
MX
PM 1:4
SD 1:1
SD 1:4
 
Fig. 6.   The anti-inflammatory activity of MX and its PM 1:4, SD 1:1 as well as SD 1:4 
microparticles. 382 M.  El-Badry:   
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Tab. 2.   The anti-inflammatory activity of MX and its PM 1:4, SD 1:1 as well as SD 1:4. 
% Swelling of induced edema  Rat 
group 
No. 
System 
No.  1hr  2hr 3hr 4hr  6hr 
1  Control 99.0±1.0 100±.05 99.0±0.05  98.01±1.0  100±0.05
2 MX 90.0±1.5 
(10.1%) 
85.05±1.1
(14.9%) 
80.01±0.55
(20.1%) 
68.04±0.6 
(32.06%) 
60.0±1.1 
(39.1%) 
3 PM  1:4  85.0±0.79 
(14.6%) 
72.4±0.5 
(27.6 %) 
68.5±0.3 
(32.9%) 
55.00±0.6 
(44.1%) 
49.0±1.5 
(51.2%) 
4 SD  1:1  80.1±1.5 
(19.9%) 
65.2±1.2 
(34.8%) 
52.3±1.8 
(48.2%) 
47.4±0.9 
(53.8%) 
42.2±0.9 
(58.8%) 
5 SD  1:4  78.2±2.0 
(22.1%) 
51.2±1.5 
(48.8%) 
40.8±1.2 
(58.8%) 
30.6±1.4 
(68.7%) 
19.2±2.1 
(80.8%) 
The value between parentheses indicates the % inhibition of edema swelling. 
PM…Physical mixture; SD…Spray drying. 
 
Experimental 
Materials 
Meloxican (MX) was kindly supplied by Medical Union Pharmaceuticals (MUP) Co. (Abu-
sultan, Ismailia, Egypt). Gelucire 50/13 with m.p. 50 ºC and HLB 13 was provided by 
Gattefosse (Cedex, France). Aerosil 200 was supplied by ICN Biomedicals, Inc. (OH, 
USA). All other materials and reagents were of analytical grade. 
Preparation of Physical Mixture 
Physical mixtures (PMs) of MX with Gelucire 50/13 at a ratio of 1:4 (w/w) were prepared by 
blending them for 10 min followed by sieving (250 µm). 
Preparation of solid dispersions (SDs) 
A Büchi mini spray dryer model B-191 (Büchi Laboratoriums-Technik AG, Flawil, 
Switzerland) with standard nozzle (0.7 mm diameter) was used to produce the dry 
powders of various formulations. MX and Gelucire 50/13 at the ratios of 1:1, 1:2 and 1:4 
(w/w) were dissolved in 100 ml ethanol. Silicium dioxide (Aerosil 200) was added to the 
clear solution at the same amount as that of the drug. The parameters were set as follows: 
liquid feed 4.5-5.0 ml/min, inlet temperature 70 °C outlet temperature 32°C, and air flow 
rate 4 psi. The product dried by and stored in a vacuum dessicator at room temperature.  
Scanning Electron Microscopy (SEM) 
The samples were sputter coated with gold (SPI, sputter, USA) and images were acquired 
using a scanning electron microscope (Joel JSM 5400LV SEM, Japan) operated at 15kV. 
Differential Scanning Calorimetry (DSC) 
The powdered sample (3–5 mg) was hermetically sealed in aluminum pans and heated 
from 25°C to 200°C at a constant rate of 10°C/min (DSC-60, Shimadzu, Japan). Data were 
processed using a TA 50I PC system with Shimadzu software programs. An indium   Physicochemical Characterization and Dissolution Properties of Meloxicam-Gelucire 50/13 Binary… 383 
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standard was used to calibrate the DSC temperature and enthalpy scale and nitrogen N2 
as a purging gas at a rate of 40 ml/min. 
X-Ray Powder Diffraction (XRD)  
Samples were irradiated with monochromatized Cu Kα radiation (1.542 Å) and analyzed 
between 2° and 40° (2θ) using a Philips FW 1700 X-ray diffractometer (Philips, 
Netherlands) setting the voltage at 40 kV and the current at 30 mA. 
Solubility Determination 
An excess amount of the sample was dispersed in 0.2 M phosphate buffer pH 7.4. After 
horizontal shaking of the samples for 48 h at 37 °C, the supernatant was filtered through a 
Millipore filter (pore size 0.45 µm). 0.5 ml of the filtrate were immediately diluted and 
assayed spectrophotometrically at 362nm [16]. All experiments were performed in 
triplicate. 
Release Rate Studies 
The USP type II (paddle) method using Electrolab dissolution tester (TDT-06N, India) was 
adopted. Samples equivalent to 50 mg of pure drug were dispersed in 900 mL of 0.1 N 
HCl or 0.2 M phosphate buffer (pH 7.4). The dissolution media were maintained at 37°C ± 
0.5°C and stirred at 50 rpm. Samples were collected periodically and replaced by fresh 
dissolution medium. After filtration through a microfilter (0.45 µm), the concentration of MX 
was determined spectrophotometrically (Jenway 6305 spectrophotometer, UK) at 362 nm. 
All experiments were carried out in triplicate. 
Anti-inflammatory activity  
An acute inflammatory activity model, the carrageenan induced rat paw edema method, 
was applied in this study [23]. The experimental procedure was in accordance with the 
guidelines of the Institutional Animal Ethical Committee of King Saud University (approval 
number KSU/IAEC/1432/12). Rats weighing about 200 ± 20 gm were divided into 5 groups 
each group has 6 rats. The animals of group 1 received Control (Gelucire 50/13) and 
group 2, 3,4 and 5 received MX, PM 1:4, SD 1:1 and SD 1:4, respectively. A sample 
equivalent to 50 mg of each formulation was administered orally to fasted rats with free 
access to water for 12 hours prior to the test. Inflammation was elicited in the rat’s left hind 
paw by s.c. injection of 0.1 ml 1.0% w/v carrageenan solution in saline. The rats were 
anaesthetized with urethane (0.5 ml intraperitoneal). The increase in the paw thickness 
was measured before carrageenan injection (time 0) and 1, 2, 3, 4 and 6 hrs after 
carrageenan administration using a dial micrometer. The percentage swelling of the paw 
and the percent inhibition of edema were calculated according the following equation [24].  
100   swelling   % ×
−
=
Vi
Vi V
 
Where: 
V = the paw thickness at each time interval (mm). 
Vi = The initial paw thickness (before carrageenan injection) (mm). 384 M.  El-Badry:   
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The average paw swelling of treated rats was compared with that of control rats (which 
received excipients of formulation without drug) and the percent inhibition of edema was 
determined using the following equation.  
100
group   control   of   swelling   %
group   treated   of   swelling % 1
  inhibition   % ×
−
=  
Statistical analysis 
Statistical analysis for the obtained results was carried out by the student t-test, at 0.05 
level of significance. 
Conclusion 
Solid dispersions of non steroidal anti-inflammatory drug (MX) were successfully prepared 
by spray drying technique using Gelucire 50/13. DSC and XRD revealed that the 
crystallinity of the drug decreased concurrently with increasing amounts of Gelucire. The 
solubility and dissolution rate of MX was increased concurrent with the Gelucire content of 
the formulations. Moreover, SDs has superior anti-inflammatory activity than the drug itself 
and its physical mixture. 
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